In the first quarter 2022 Latvia is expected to receive 2,076,780 doses, 1,377,450 in the second quarter, 897,962 in the third and 383,260 in the fourth.
Pavļuts stated at the government meeting that the number of vaccines was calculated so as to enable each resident to get a booster twice.
Latvia has also applied for the vaccines of a number of manufacturers that have not yet been approved in the European Union: CureVac, Sanofi, Novavax and Valneva.
The minister said that an informative report on the costs of the vaccine portfolio is currently being prepared. It is developed in an attempt to provide as many vaccines as possible, “so that if something unknown happens, we are able to meet the needs of the people of Latvia”.
Most vaccines Latvia has applied for are mRNA vaccines – 1,638,000 doses will be received from Pfizer/BioNTech, 914,600 doses from Moderna. However, there will also be 575,700 doses of Johnson & Johnson and 525,700 AstraZeneca.
Pavļuts also said that Latvia currently has over a million doses in stock.
